Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 422.32
- Piotroski Score 1.00
- Grade Buy
- Symbol (BLTE)
- Company Belite Bio, Inc
- Price $82.81
- Changes Percentage (0.06%)
- Change $0.05
- Day Low $80.00
- Day High $83.95
- Year High $86.53
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/28/2025
- Fiscal Year End N/A
- Average Stock Price Target $60.00
- High Stock Price Target $60.00
- Low Stock Price Target $60.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.13
- Trailing P/E Ratio -42.89
- Forward P/E Ratio -42.89
- P/E Growth -42.89
- Net Income $-31,632,000
Income Statement
Quarterly
Annual
Latest News of BLTE
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Estimating The Intrinsic Value Of Belite Bio, Inc (NASDAQ:BLTE)
The fair value estimate for Belite Bio is 8.1% lower than the analyst price target. Using a DCF model, the intrinsic value is calculated as US$1.5b, indicating the stock is about fair value with a 3....
By Yahoo! Finance | 5 months ago
